Glenmede Trust Co. NA increased its stake in Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) by 125.9% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 727,781 shares of the life sciences company's stock after purchasing an additional 405,624 shares during the period. Glenmede Trust Co. NA owned approximately 0.94% of Integra LifeSciences worth $13,224,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Cooke & Bieler LP lifted its position in Integra LifeSciences by 12.4% during the 2nd quarter. Cooke & Bieler LP now owns 3,514,281 shares of the life sciences company's stock worth $102,406,000 after buying an additional 388,710 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in Integra LifeSciences by 0.7% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,785,009 shares of the life sciences company's stock worth $52,014,000 after buying an additional 12,766 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in Integra LifeSciences by 15.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 944,282 shares of the life sciences company's stock worth $17,158,000 after buying an additional 125,620 shares in the last quarter. D. E. Shaw & Co. Inc. raised its holdings in shares of Integra LifeSciences by 64.6% in the 2nd quarter. D. E. Shaw & Co. Inc. now owns 855,352 shares of the life sciences company's stock valued at $24,925,000 after purchasing an additional 335,557 shares during the period. Finally, AQR Capital Management LLC raised its holdings in shares of Integra LifeSciences by 90.9% in the 2nd quarter. AQR Capital Management LLC now owns 611,798 shares of the life sciences company's stock valued at $17,436,000 after purchasing an additional 291,326 shares during the period. 84.78% of the stock is owned by institutional investors and hedge funds.
Integra LifeSciences Stock Performance
Shares of NASDAQ:IART traded up $0.04 on Friday, reaching $24.58. 249,836 shares of the company's stock were exchanged, compared to its average volume of 1,089,028. The company has a fifty day moving average of $20.63 and a 200-day moving average of $24.01. Integra LifeSciences Holdings Co. has a twelve month low of $16.81 and a twelve month high of $45.42. The company has a market capitalization of $1.90 billion, a price-to-earnings ratio of -273.30, a PEG ratio of 0.83 and a beta of 1.08. The company has a current ratio of 1.20, a quick ratio of 0.73 and a debt-to-equity ratio of 0.79.
Integra LifeSciences (NASDAQ:IART - Get Free Report) last announced its earnings results on Monday, November 4th. The life sciences company reported $0.41 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.39 by $0.02. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The firm had revenue of $380.80 million for the quarter, compared to analyst estimates of $375.81 million. During the same quarter in the prior year, the business posted $0.76 EPS. The business's revenue was down .4% compared to the same quarter last year. On average, research analysts predict that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current fiscal year.
Analyst Ratings Changes
A number of equities research analysts have recently issued reports on IART shares. Citigroup upped their target price on shares of Integra LifeSciences from $16.00 to $22.00 and gave the company a "sell" rating in a report on Tuesday, November 5th. BTIG Research raised shares of Integra LifeSciences from a "sell" rating to a "neutral" rating in a report on Monday, October 7th. Truist Financial dropped their target price on shares of Integra LifeSciences from $26.00 to $21.00 and set a "hold" rating on the stock in a report on Monday, October 14th. Finally, Bank of America dropped their target price on shares of Integra LifeSciences from $26.00 to $18.00 and set an "underperform" rating on the stock in a report on Monday, October 7th. Three investment analysts have rated the stock with a sell rating, five have issued a hold rating and one has given a buy rating to the stock. According to MarketBeat, Integra LifeSciences has an average rating of "Hold" and a consensus price target of $24.00.
Get Our Latest Report on IART
About Integra LifeSciences
(
Free Report)
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.
Further Reading
Before you consider Integra LifeSciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Integra LifeSciences wasn't on the list.
While Integra LifeSciences currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
